Do analysts rate APLT or KVAC?

Applied Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, equities analysts clearly believe Applied Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, APLT or KVAC?

Keen Vision Acquisition has lower revenue, but higher earnings than Applied Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Applied Therapeutics $1M 15.86 -$105.62M -$0.10 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is APLT or KVAC more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Keen Vision Acquisition N/A N/A N/A

Is INKT or APLT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -92.37% Applied Therapeutics N/A -340.84% -175.00%

Do analysts recommend APLT or XLO?

Applied Therapeutics currently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor APLT or XLO?

In the previous week, Applied Therapeutics and Applied Therapeutics both had 1 articles in the media. Applied Therapeutics' average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is APLT or ELTX more profitable?

Applied Therapeutics' return on equity of -340.84% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Elicio Therapeutics N/A -1,266.43% -139.94%

Does the media favor APLT or ELTX?

In the previous week, Elicio Therapeutics had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for Elicio Therapeutics and 1 mentions for Applied Therapeutics. Elicio Therapeutics' average media sentiment score of 0.89 beat Applied Therapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elicio Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is APLT or EXOZ more profitable?

eXoZymes' return on equity of -292.15% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% eXoZymes N/A -292.15% -158.66%

Applied Therapeutics (APLT) Competitors

$0.10 0.00 (0.00%)

As of 09/18/2026

Compare

APLT vs. KVAC, INKT, XLO, ELTX, and EXOZ

Should you buy Applied Therapeutics stock or one of its competitors? Applied Therapeutics's main competitors and comparable companies include Keen Vision Acquisition (KVAC), MiNK Therapeutics (INKT), Xilio Therapeutics (XLO), Elicio Therapeutics (ELTX), and eXoZymes (EXOZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Applied Therapeutics compare to Keen Vision Acquisition?

Applied Therapeutics (NASDAQ:APLT) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Keen Vision Acquisition's return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Keen Vision Acquisition	N/A	N/A	N/A

Applied Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, equities analysts clearly believe Applied Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Keen Vision Acquisition has lower revenue, but higher earnings than Applied Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

In the previous week, Applied Therapeutics had 1 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 1 mentions for Applied Therapeutics and 0 mentions for Keen Vision Acquisition. Applied Therapeutics' average media sentiment score of 0.00 equaled Keen Vision Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Keen Vision Acquisition	Neutral

Summary

Applied Therapeutics beats Keen Vision Acquisition on 5 of the 9 factors compared between the two stocks.

How does Applied Therapeutics compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MiNK Therapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Applied Therapeutics	N/A	-340.84%	-175.00%

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 185.71%. Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Applied Therapeutics had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 1 mentions for Applied Therapeutics and 0 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Applied Therapeutics	Neutral

MiNK Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

MiNK Therapeutics has higher earnings, but lower revenue than Applied Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Summary

Applied Therapeutics beats MiNK Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Applied Therapeutics compare to Xilio Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Xilio Therapeutics has higher revenue and earnings than Applied Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Xilio Therapeutics	$64.09M	0.92	-$35.04M	-$1.64	N/A

In the previous week, Applied Therapeutics and Applied Therapeutics both had 1 articles in the media. Applied Therapeutics' average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Applied Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Applied Therapeutics currently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Applied Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market.

Applied Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Xilio Therapeutics' return on equity of -71.99% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

Summary

Applied Therapeutics beats Xilio Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Applied Therapeutics compare to Elicio Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Elicio Therapeutics has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Applied Therapeutics currently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Elicio Therapeutics has a consensus price target of $19.75, suggesting a potential upside of 904.58%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Elicio Therapeutics is more favorable than Applied Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Applied Therapeutics' return on equity of -340.84% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

In the previous week, Elicio Therapeutics had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for Elicio Therapeutics and 1 mentions for Applied Therapeutics. Elicio Therapeutics' average media sentiment score of 0.89 beat Applied Therapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Applied Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elicio Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

Summary

Elicio Therapeutics beats Applied Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Applied Therapeutics compare to eXoZymes?

Applied Therapeutics (NASDAQ:APLT) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Applied Therapeutics presently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

eXoZymes has lower revenue, but higher earnings than Applied Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
eXoZymes	$70K	825.26	-$9.16M	-$1.19	N/A

Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, indicating that its share price is 214% more volatile than the broader market.

98.3% of Applied Therapeutics shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

eXoZymes' return on equity of -292.15% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
eXoZymes	N/A	-292.15%	-158.66%

In the previous week, Applied Therapeutics had 1 more articles in the media than eXoZymes. MarketBeat recorded 1 mentions for Applied Therapeutics and 0 mentions for eXoZymes. Applied Therapeutics' average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
Applied Therapeutics	Neutral
eXoZymes	Neutral

Summary

Applied Therapeutics beats eXoZymes on 7 of the 13 factors compared between the two stocks.

Get Applied Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLT vs. The Competition

Export

Metric	Applied Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.86M	$3.93B	$7.27B	$13.23B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-1.03	14.13	275.26	25.82
Price / Sales	15.86	1,579.45	693.22	102.97
Price / Cash	N/A	41.62	28.04	34.72
Price / Book	0.21	15.70	10.60	6.40
Net Income	-$105.62M	-$22.86M	$3.49B	$358.17M
7 Day Performance	N/A	-1.19%	-0.10%	0.69%
1 Month Performance	N/A	-4.48%	-2.63%	-2.77%
1 Year Performance	-76.31%	38.48%	18.51%	6.25%

Applied Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLT Applied Therapeutics	1.3508 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30	News Coverage
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
INKT MiNK Therapeutics	1.9215 of 5 stars	$12.13 +1.9%	$35.00 +188.5%	-20.1%	$60.73M	N/A	N/A	30	High Trading Volume
XLO Xilio Therapeutics	0.0518 of 5 stars	$8.93 -0.4%	N/A	-16.4%	$59.02M	$43.77M	N/A	70	News Coverage Analyst Downgrade
ELTX Elicio Therapeutics	2.825 of 5 stars	$2.11 -3.2%	$19.75 +836.0%	-83.3%	$57.29M	N/A	N/A	N/A	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLT) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Applied Therapeutics (APLT) Competitors

APLT vs. KVAC, INKT, XLO, ELTX, and EXOZ

How does Applied Therapeutics compare to Keen Vision Acquisition?

Summary

How does Applied Therapeutics compare to MiNK Therapeutics?

Summary

How does Applied Therapeutics compare to Xilio Therapeutics?

Summary

How does Applied Therapeutics compare to Elicio Therapeutics?

Summary

How does Applied Therapeutics compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Applied Therapeutics (APLT) Competitors

APLT vs. KVAC, INKT, XLO, ELTX, and EXOZ

How does Applied Therapeutics compare to Keen Vision Acquisition?

Is APLT or KVAC more profitable?

Do analysts rate APLT or KVAC?

Which has better earnings and valuation, APLT or KVAC?

Do institutionals and insiders believe in APLT or KVAC?

Which has more volatility & risk, APLT or KVAC?

Does the media favor APLT or KVAC?

Summary

How does Applied Therapeutics compare to MiNK Therapeutics?

Do insiders & institutionals hold more shares of INKT or APLT?

Is INKT or APLT more profitable?

Do analysts prefer INKT or APLT?

Does the media prefer INKT or APLT?

Which has more volatility & risk, INKT or APLT?

Which has preferable valuation and earnings, INKT or APLT?

Summary

How does Applied Therapeutics compare to Xilio Therapeutics?

Which has higher earnings & valuation, APLT or XLO?

Does the media favor APLT or XLO?

Do institutionals & insiders hold more shares of APLT or XLO?

Do analysts recommend APLT or XLO?

Which has more risk and volatility, APLT or XLO?

Is APLT or XLO more profitable?

Summary

How does Applied Therapeutics compare to Elicio Therapeutics?

Which has stronger earnings and valuation, APLT or ELTX?

Do analysts recommend APLT or ELTX?

Is APLT or ELTX more profitable?

Does the media favor APLT or ELTX?

Do insiders and institutionals hold more shares of APLT or ELTX?

Which has more volatility & risk, APLT or ELTX?

Summary

How does Applied Therapeutics compare to eXoZymes?

Do analysts rate APLT or EXOZ?

Which has higher earnings & valuation, APLT or EXOZ?

Which has more volatility & risk, APLT or EXOZ?

Do institutionals and insiders have more ownership in APLT or EXOZ?

Is APLT or EXOZ more profitable?

Does the media prefer APLT or EXOZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools